Aug 2026· Endocrine, Metabolic & Immune Disorders - Drug Targets· 0 citations
Medicine
TL;DR
These findings bridge the gap between metabolic lipotoxicity and epigenetic regulation, suggesting that lactylation acts as a critical driver in NAFLD pathogenesis.
Abstract
Background
Nonalcoholic fatty liver disease (NAFLD) is characterized by profound metabolic reprogramming. Recent evidence suggests that lactate, beyond its role as a metabolic waste product, may modulate histone lactylation, linking metabolic stress to the epigenetic regulation of disease progression. However, the specific lactate-related gene (LRG) signatures driving NAFLD remain to be elucidated.
Methods
We integrated transcriptomic mining of the GSE164760 dataset with in vivo validation to decode the LRG landscape. Differentially expressed LRGs were identified using strict thresholds and subsequently intersected with the GeneCards database. Functional enrichment (GO/KEGG) and Protein-Protein Interaction (PPI) networks were constructed to screen for hub genes. Key biomarkers were subsequently corroborated in a high-fat diet (HFD)- induced rat NAFLD model via Western blotting.
Results
A total of 98 differentially expressed LRGs were identified, which were primarily enriched in molecular catabolism and xenobiotic stress responses. From this network, eight pivotal hub genes were distilled: CREBBP, EP300, HDAC1, HIF1A, PARP1, SIRT1, STAT3, and TP53. Diagnostic modeling demonstrated their predictive value, with AUC scores ranging from 0.60 to 0.81, among which PARP1 and STAT3 exhibited high diagnostic potential (AUC > 0.80). Experimental validation in the rat model confirmed the disruption of this metabolic-epigenetic regulatory module, revealing significant dysregulation in protein expression that reflects a compensatory stress response to lipotoxicity.
Discussion
These findings bridge the gap between metabolic lipotoxicity and epigenetic regulation, suggesting that lactylation acts as a critical driver in NAFLD pathogenesis.
Conclusion
This study delineates a preliminary, hypothesis-generating lactate-associated gene signature in NAFLD, highlighting a complex regulatory network governing hepatocyte metabolic plasticity and survival. These eight core biomarkers offer promising tissue-based targets for mechanistic intervention, though further validation in peripheral blood is required to establish their non-invasive diagnostic utility.
Five genes are identified as "protective factors", and their downregulation is associated with NAFLD progression, and the remaining three genes exhibit inconsistent expression patterns, suggesting bidirectional regulation.
Xiao-Cui Wang, Xinhe Wang, Liang Zhao et al.· Clinical and Experimental Me...· 0 citations
A lactylation-related diagnostic signature is established, metabolic-immune crosstalk is revealed, and early clinical diagnosis of kidney fibrosis is supported.
Ye Kuang, Xiuhong Xiang, Chuan-Mei Peng et al.· iScience· 0 citations
Three candidate biomarkers co-dysregulated across T2DM and MCI transcriptomes and associated with uric acid metabolism are identified and considered hypothesis-generating and require validation in larger independent cohorts.
Yan Liu, Dongmei Kang, Yuan Lei· Experimental biology and med...· 0 citations
A profound, stage-dependent disruption of the liver-adipose tissue axis during metabolic-driven hepatic oncogenesis is demonstrated, positioning ANGPTL2, ANGPT1, and ITLN1 as promising biomarkers and potential therapeutic targets in HCC.
J. López-Cánovas, J. M. Zamora Olaya, I. Sáez-Escobar et al.· European Journal of Endocrin...· 0 citations
Hub genes including MVP, WISP1, FCN1, AMPD3, RARRES1, FTL, and KRT14 possess promising auxiliary diagnostic potential, which provides novel clues for subsequent clinical evaluation research on DCM.
Functional enrichment analysis indicates that BPA-induced NAFLD and OA comorbidity pathways are enriched in muscle cell proliferation, DNA metabolism, and inflammation pathways, indicating that limiting BPA exposure or modulating the RHOB pathway represents a viable approach for intervening in related diseases.